sameAs
Prevention of HIV-1 infection with early antiretroviral therapyIdentifying Recent HIV Infections: From Serological Assays to GenomicsChildren who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysisGenomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposureThe development and utility of a clinical algorithm to predict early HIV-1 infection.Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.HIV-1 subtype C in vitro growth and coreceptor utilization.Strengthening biostatistics resources in sub-Saharan Africa: research collaborations through U.S. partnerships.Short Communication: Low False Recent Rate of Limiting Antigen-Avidity Assay Combined with HIV-1 RNA Data in Botswana.Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection.Temporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCTHIV-1 drug mutations in children from northern TanzaniaFive-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan AfricaTherapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection.Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialBirth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infants.High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in BotswanaHighly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.A randomized trial of multivitamin supplements and HIV disease progression and mortality.Vitamin D insufficiency in HIV-infected pregnant women receiving antiretroviral therapy is not associated with morbidity, mortality or growth impairment in their uninfected infants in Botswana.Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in BotswanaImpact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimenResponse to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana.Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.Risk factors for mortality among human immunodeficiency virus-exposed and unexposed infants admitted to a neonatal intensive care unit in BotswanaIncreased risk of severe infant anemia after exposure to maternal HAART, Botswana.Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.Immune activation markers in peripartum women in Botswana: association with feeding strategy and maternal morbidity.Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancyA fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen.High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.HIV-1 Subtype C Phylodynamics in the Global EpidemicHighly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana.Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor
P50
Q24634688-9CCFECBD-B362-4E81-81F7-98DB65F1B426Q26778001-190F1337-7F69-41F0-AC35-3E825A292FCEQ28731813-845A5086-9386-4F70-84BF-8E38AB9D7E29Q29417004-EEBF0C9F-63C2-4347-B517-0D1E99E220CAQ30232921-30EDE4BA-D419-45CC-9BB4-2D3D4370035EQ30330385-F7DEEE14-70E3-441B-87BF-E4ACFFE44717Q30352511-E051ECBF-6BAF-48C8-BBF8-398B645EBA22Q30400637-48E27BD3-861F-4A16-B1E4-B0037F175F78Q31119048-650FAD61-A445-40EA-B6E5-B10339CB853CQ33625545-3FA0605A-9D26-4178-8496-D4C70F0D5BC2Q33686897-0E630CB7-2900-4187-8A12-3DCBD6C155CBQ33746054-D41A3F6B-7510-40E1-9C3F-696EF166A10AQ33782796-16DA6BD5-895C-492A-A937-2629A6EFDB7FQ33797490-5FCB9FC7-9F0E-422B-9589-858CB9D036A0Q33887266-840F2623-A785-49E8-A891-E770011A488DQ34019433-1CEE92AF-6673-49DF-AFF0-B9163E9BA665Q34045503-9A5F6497-9C1E-41AD-A186-261611C8BF03Q34086963-00F97F68-9A50-48E8-B5C7-BA9C90839ED8Q34104017-91E6CB8B-2F3D-48E3-897B-41B48F544E5CQ34181776-B92CEE2E-72EB-4A64-AF97-C02B2845E5FFQ34306176-FEEDD53A-DD22-418B-BA56-C2D16B583AA6Q34330475-14E186ED-D975-4AAA-9DF6-E0BBF6BCFACBQ34437771-C2B809BB-2336-4633-B61A-34B1AE3F96C5Q34500824-E6AA9F05-9BE0-4D77-A6AA-7EB7D4146714Q34680647-CEA34D85-36CB-4BC4-84E3-CF1E5D99AD37Q34732899-3F06D2C8-EEA8-437B-B4A0-C0E37A8263F5Q34743329-AA2AE9DF-C008-419B-B9D4-313738831C5FQ34744722-11E95DE1-1545-4F30-8BA1-C02D03CEFBE4Q34927469-F7758973-E421-41E6-9007-5C5F909E78C2Q35004909-E18732D6-1A81-4906-B2AC-0C239D92FAA2Q35026602-C358EFB2-BCEA-4DBD-BD33-8DA29F400FD7Q35037981-E7BAE7AE-1EB6-40AD-A883-DEE1B6B2B859Q35076519-AAED248B-09D3-40FC-B99F-540F68D69197Q35127830-527D86CB-4441-49A9-8031-A15F4E7AD6BDQ35129403-F4262810-B1C1-47B2-9168-9149F783D128Q35143862-246BF960-8C85-481C-B43B-C055C33799F5Q35215399-C642C9A6-BD7B-49A5-ADCB-0F853B706050Q35260218-DCB1AE2B-211E-49A2-ACC7-C0243A4A7C34Q35386228-FDB01058-DA72-4C02-A46E-37107E594430Q35677825-B23C5E89-98BA-4D8C-9794-235FDF712B63
P50
description
American virologist
@en
US-amerikanischer Mediziner und Virologe
@de
usona virusologo
@eo
virolojiste american
@lfn
viroloog
@nl
virólogo estadounidense
@es
طبيب
@ar
name
Max Essex
@ast
Max Essex
@da
Max Essex
@de
Max Essex
@en
Max Essex
@es
Max Essex
@fo
Max Essex
@fr
Max Essex
@ga
Max Essex
@is
Max Essex
@it
type
label
Max Essex
@ast
Max Essex
@da
Max Essex
@de
Max Essex
@en
Max Essex
@es
Max Essex
@fo
Max Essex
@fr
Max Essex
@ga
Max Essex
@is
Max Essex
@it
altLabel
Essex M
@en
Essex M.
@en
Essex
@en
Essex, Max
@en
M Essex
@ast
M Essex
@en
M. Essex
@en
prefLabel
Max Essex
@ast
Max Essex
@da
Max Essex
@de
Max Essex
@en
Max Essex
@es
Max Essex
@fo
Max Essex
@fr
Max Essex
@ga
Max Essex
@is
Max Essex
@it
P106
P227
P101
P19
P2031
1936-01-01T00:00:00Z
P21
P214
720145857089122921976
P227
1089190921
P31
P373
P496
0000-0002-4576-7841
P569
1939-08-17T00:00:00Z
P734
P735
P7859
viaf-720145857089122921976